Tovok: Preliminary Phase II data

Preliminary data from 74 evaluable patients in an ongoing, open-label Phase II trial showed that 22% of patients treated with 50 mg daily Tovok (n=34) achieved a partial response vs. 13% of patients treated with Erbitux cetuximab (n=40). Diarrhea and skin-related disorders were the most common Tovok-related adverse events. Patients were allowed to cross over to the opposite treatment arm upon disease progression. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...